Elutia (NASDAQ:ELUT - Free Report) had its target price lowered by Cantor Fitzgerald from $6.00 to $5.00 in a research note issued to investors on Friday morning, Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.
Elutia Price Performance
Elutia stock traded up $0.48 during trading hours on Friday, hitting $3.28. The stock had a trading volume of 57,994 shares, compared to its average volume of 12,201. Elutia has a one year low of $1.10 and a one year high of $4.19. The business's 50 day simple moving average is $3.09 and its 200-day simple moving average is $2.75.
Elutia (NASDAQ:ELUT - Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.75) EPS for the quarter. The business had revenue of $6.69 million during the quarter. Analysts expect that Elutia will post -1.68 EPS for the current year.
Hedge Funds Weigh In On Elutia
A hedge fund recently bought a new stake in Elutia stock. Verdence Capital Advisors LLC acquired a new position in shares of Elutia Inc. (NASDAQ:ELUT - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,410 shares of the company's stock, valued at approximately $45,000. Verdence Capital Advisors LLC owned about 0.06% of Elutia at the end of the most recent reporting period. 74.03% of the stock is currently owned by hedge funds and other institutional investors.
About Elutia
(
Get Free Report)
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
See Also
Before you consider Elutia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elutia wasn't on the list.
While Elutia currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
